| ABIOMED is a provider of medical devices that provide circulatory support and oxygenation. Co.'s existing products include: Impella 2.5®, which is a percutaneous heart pump with a motor and sensors; Impella CP®, which is primarily used by either interventional cardiologists to support patients in the cath lab or by cardiac surgeons in the heart surgery suite; Impella 5.0® and Impella LD®, which are percutaneous heart pumps with motors and sensors for use primarily in the heart surgery suite; Impella 5.5®, which is designed to be a percutaneous heart pump with motors and sensors; and Abiomed Breethe OXY-1 System, which is a portable external respiratory assistance device. |
When researching a stock like ABIOMED, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from ABMD Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for ABMD stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of these ways is called the Relative Strength Index, or RSI. This popular indicator, originally developed in the 1970's by J. Welles Wilder, looks at a 14-day moving average of a stock's gains on its up days, versus its losses on its down days. The resulting ABMD RSI is a value that measures momentum, oscillating between "oversold" and "overbought" on a scale of zero to 100. A reading below 30 is viewed to be oversold, which a bullish investor could look to as a sign that the selling is in the process of exhausting itself, and look for entry point opportunities. A reading above 70 is viewed to be overbought, which could indicate that a rally in progress is starting to get crowded with buyers. If the rally has been a long one, that could be a sign that a pullback is overdue.